We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.

Use ofdoxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer / Livi, L; Meattini, I; de Luca Cardillo, C; Scotti, V; Agresti, B; Franzese, C; Sanchez, L; Nori, J; Bertocci, S; Cassani, S; Bianchi, S; Cataliotti, L; Biti, G.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1973-9478. - STAMPA. - 23:(2011), pp. 36-39. [10.1179/joc.2011.23.1.36]

Use ofdoxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.

LIVI, LORENZO;MEATTINI, ICRO;BIANCHI, SIMONETTA;CATALIOTTI, LUIGI;BITI, GIAMPAOLO
2011

Abstract

We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.
2011
23
36
39
Livi, L; Meattini, I; de Luca Cardillo, C; Scotti, V; Agresti, B; Franzese, C; Sanchez, L; Nori, J; Bertocci, S; Cassani, S; Bianchi, S; Cataliotti, L; Biti, G.
File in questo prodotto:
File Dimensione Formato  
Livi 2011 J Chem_AC plus docetaxel.pdf

Accesso chiuso

Descrizione: Paper
Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 160.68 kB
Formato Adobe PDF
160.68 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/593593
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact